- Motif Bio said it had delayed a new drug application to the US Food and Drug Administration for a skin-infection treatment in order improve the quality of its submission.

'In consultation with its advisers, the company has decided that in order to ensure a complete and high-quality submission, it would be prudent to take additional time,' Motif Bio said.

Consequently, it now expected the request would be submitted during the second quarter of 2018.

'There are many components that go into an NDA submission and our aggressive timeline was contingent upon all outstanding items being completed to provide sufficient time to quality check and then publish the document,' chief executive Graham Lumsden said.

'Most components are complete, but given the importance of the submission, we made the decision that it was in the best interests of the company and all stakeholders to allow more time to ensure we submit the strongest possible application.'

At 9:53am: [LON:MTFB] Motif Bio Plc Ord 1p share price was -2.6p at 32.95p

Story provided by